Home
>
Glaxosmithkline Pharmaceuticals Ltd Financials

Glaxosmithkline Pharmaceuticals Ltd Financial Statement

Glaxosmithkline Pharmaceuticals Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

(Rs. CR)	Mar 2024	Dec 2023	Sep 2023
Revenue	943.14	833.32	981.85
Operating Expense	655.56	750.78	666.8
Net Profit	193.08	45.49	215.54
Net Profit Margin	20.47	5.46	21.95
Earning Per Share	11.29	2.69	12.72
EBIDTA	273.11	94.24	324.68
Effective Tax Rate	21.27	37.95	28.76

(Rs. Cr)

Revenue

Operating Expense

Net Profit

Net Profit Margin

Earning Per Share

EBIDTA

Effective Tax Rate

943.14

655.56

193.08

20.47

11.29

273.11

21.27

833.32

750.78

45.49

5.46

2.69

94.24

37.95

981.85

666.8

215.54

21.95

12.72

324.68

28.76

Glaxosmithkline Pharmaceuticals Ltd Profit & Loss

*All values are in Rs. Cr

Consolidated

Standalone

Particulars	Mar 2023	Mar 2022	Mar 2021
Total Revenue Annual	3,251.72	3,278.03	2,925.6
Operating Expenses Annual	2,447.44	2,516.15	2,327.46
Operating Profit Annual	907.02	2,163.18	607.01
Interest Annual	1.81	2	3.53
Depreciation	39.97	43.96	53.72
Net Profit Annual	607.64	380.77	287.27
Tax Annual	228.76	398.28	166.72

Particulars

Total Revenue Annual

Operating Expenses Annual

Operating Profit Annual

Interest Annual

Depreciation

Net Profit Annual

Tax Annual

3,251.72

2,447.44

907.02

1.81

39.97

607.64

228.76

3,278.03

2,516.15

2,163.18

43.96

380.77

398.28

2,925.6

2,327.46

607.01

3.53

53.72

287.27

166.72

Glaxosmithkline Pharmaceuticals Ltd Cash Flow

*All values are in Rs. Cr

Consolidated

Standalone

Particulars	Mar 2023	Mar 2022	Mar 2021
Cash Flow at the Beginning	286.19	405.19	104.81
Cash Flow from Operations	484.23	810.75	577.91
Cash Flow from Investing	807.85	-405.51	418.03
Cash Flow from Financing	-1,543.32	-524.24	-695.56
Cash Flow at the End	34.94	286.19	405.19

Particulars

Cash Flow at the Beginning

Cash Flow from Operations

Cash Flow from Investing

Cash Flow from Financing

Cash Flow at the End

286.19

484.23

807.85

-1,543.32

34.94

405.19

810.75

-405.51

-524.24

286.19

104.81

577.91

418.03

-695.56

405.19

Glaxosmithkline Pharmaceuticals Ltd Key Ratios

*All values are in Rs. Cr

Consolidated

Standalone

Particulars	Mar 2023	Mar 2022	Mar 2021
PBDIT Margin (%)	27.89	25.53	24.23
PBIT Margin (%)	25.87	23.45	21.54
PBT Margin (%)	11.42	11.51	15.43
Net PROFIT Margin (%)	18.9	52.54	12.24
Return On Networth / Equity (%)	27.73	81.31	28.86
Return On Networth /Employed(%)	33.92	32.55	32.43
Return On Assets (%)	24.75	73.03	18.49
Total Debt / Equity(X)	0.01	0.01	0.01
Asset Turnover Ratio (%)	1.31	1.39	1.51

Particulars

PBDIT Margin (%)

PBIT Margin (%)

PBT Margin (%)

Net PROFIT Margin (%)

Return On Networth / Equity (%)

Return On Networth / Employed(%)

Return On Assets (%)

Total Debt / Equity(X)

Asset Turnover Ratio (%)

27.89

25.87

11.42

18.9

27.73

33.92

24.75

0.01

1.31

25.53

23.45

11.51

52.54

81.31

32.55

73.03

0.01

1.39

24.23

21.54

15.43

12.24

28.86

32.43

18.49

0.01

1.51

Glaxosmithkline Pharmaceuticals Ltd Balance Sheet

*All values are in Rs. Cr

Consolidated

Standalone

Particulars	Mar 2023	Mar 2022	Mar 2021
Fixed Assets Annual	328.9	329.44	385.56
Total Current Assets Annual	2,494.26	3,708.03	2,202.64
Non Current Assets Annual	832.32	925.25	912.01
Total Shareholders Funds Annual	1,741.27	2,662.96	1,478.26
Total Assets Annual	3,326.58	4,633.28	3,114.65

Particulars

Fixed Assets Annual

Total Current Assets Annual

Non Current Assets Annual

Total Shareholders Funds Annual

Total Assets Annual

328.9

2,494.26

832.32

1,741.27

3,326.58

329.44

3,708.03

925.25

2,662.96

4,633.28

385.56

2,202.64

912.01

1,478.26

3,114.65

Glaxosmithkline Pharmaceuticals Ltd Earning Calls

Mar 2024

EPS beaten by -0.96 %

Open Demat Account

50 Years

of Trust & Legacy

₹0 AMC

for First Year

₹0 Brokerage

on Delivery, Intraday, Currency and NSE F&O

Dividend Pages

Get Your FAQs Right

What is Glaxosmithkline Pharmaceuticals Ltd's share capital?

As of May 20, 2024, Glaxosmithkline Pharmaceuticals Ltd has a market capitalization of 32,917.29 Cr. Value Research classifies it as a Large-Cap company.

Is Glaxosmithkline Pharmaceuticals Ltd debt-free?

Yes, Glaxosmithkline Pharmaceuticals Ltd is debt-free with a debt-to-equity ratio of 0.01.

What is Glaxosmithkline Pharmaceuticals Ltd's total revenue?

In FY 2023, Glaxosmithkline Pharmaceuticals Ltd recorded a total revenue of approximately 3,453.71 Cr marking a significant milestone in the company's financial performance.

What is the future growth of Glaxosmithkline Pharmaceuticals Ltd?

Glaxosmithkline Pharmaceuticals Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.1% and 0.0% annually, respectively..

What is the PE Ratio of Glaxosmithkline Pharmaceuticals Ltd?

Glaxosmithkline Pharmaceuticals Ltd's current PE ratio is 55.80.

What is Glaxosmithkline Pharmaceuticals Ltd's Return on Capital Employed (ROCE)?

Glaxosmithkline Pharmaceuticals Ltd's ROCE averaged 43.4% from the FY ending March 2022 to 2024, with a median of 47.9%. It peaked at 53.5% in March 2024, reflecting strong capital efficiency over the period..

What is the latest EBIT (Earnings Before Interest and Taxes) of Glaxosmithkline Pharmaceuticals Ltd?

Glaxosmithkline Pharmaceuticals Ltd's latest EBIT is Rs. 817.99 Cr, surpassing the average EBIT of Rs. 1,251.42 Cr over the 5 years..